Other biomarkers are being studied, such as the tumor proportion score (TPS; evaluates expression of PD-L1 on tumor cells) [12], tumor immune dysfunction and exclusion (TIDE) signature (stratifies patients into high or low cytotoxic T lymphocyte count based on gene signature) [13], and Immunoscore (based on the density of total and cytotoxic tumor infiltrating T cell). The gene discussed is CD274; the disease is neoplasm.